Search

Colyn C Cain

from Bethesda, MD
Age ~57
Get Report
Also known as:
Colyn B Cargile, Cain Colyn, Cargile Colyn
Phone and address:
8013 Whittier Blvd, Bethesda, MD 20817
(301) 664-9594
Related to:
Lori R Cargile, 59Christopher J Cain, 61Chris Cain, 61Hannah C CainLee S CargilePatricia Z Cargile, 82Melanie K Cain, 63Lloyd S Cargile, 86Caleb B Cain, 33Jordan L Cargile, 27
Connected to:
Abbey L Cain, 30Abraham Cain, 64Adam J Cain, 73Aidan T Cain, 29Alanna M Cain, 37Alison L Cain, 64Alvajoy L Cain, 63Alvin R Cain, 69Alysia R Cain, 32Amelia C Cain, 34

Colyn Cain Phones & Addresses

  • 8013 Whittier Blvd, Bethesda, MD 20817 (301) 664-9594
  • 4309 Kentbury Dr, Bethesda, MD 20814 (301) 951-4489
  • Rockville, MD
  • Baltimore, MD
  • 8013 Whittier Blvd, Bethesda, MD 20817

Work

Company: JOHNS HOPKINS HOSPITAL Address: 600 N Wolfe St, Baltimore, MD 21287 Phones: (410) 955-5080 (410) 955-1464

Education

School / High School: University Of Maryland At Baltimore / Professional Schools

Skills

Cell Culture • Molecular Biology • Genetics • Cell Biology • Cancer • Clinical Research • Genomics • Laboratory

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Clinical Cytogenetics, 1999

Industries

Hospital & Health Care

Specialities

Clinical Cytogenetics

Professional Records

Medicine Doctors

Colyn Cain Photo 1

Dr. Colyn C Cain, Baltimore MD - PHD

View page
Specialties:
Clinical Cytogenetics
Address:
600 N Wolfe St, Baltimore, MD 21287
(410) 955-3476 (Phone), (410) 614-8766 (Fax)

JOHNS HOPKINS HOSPITAL
600 N Wolfe St, Baltimore, MD 21287
(410) 955-5080 (Phone), (410) 955-1464 (Fax)
Certifications:
Clinical Cytogenetics, 1999
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
600 N Wolfe St, Baltimore, MD 21287

JOHNS HOPKINS HOSPITAL
600 N Wolfe St, Baltimore, MD 21287

The Johns Hopkins Hospital
1800 Orleans Street, Baltimore, MD 21287
Education:
Medical School
University Of Maryland At Baltimore / Professional Schools
Medical School
The Johns Hopkins Hospital

Resumes

Resumes

Colyn Cain Photo 2

Colyn Cain

View page
Location:
Chantilly, VA
Industry:
Hospital & Health Care
Skills:
Cell Culture
Molecular Biology
Genetics
Cell Biology
Cancer
Clinical Research
Genomics
Laboratory
Certifications:
American Board of Medical Genetics
Clinical Cytogenetics

Publications

Us Patents

Amplified Cancer Target Genes Useful In Diagnosis And Thereapeutic Screening

View page
US Patent:
20060134622, Jun 22, 2006
Filed:
Dec 19, 2003
Appl. No.:
10/540311
Inventors:
Meena Augustus - Gaithersburg MD, US
Stephen Horrigan - Gaithersburg MD, US
Colyn Cain - Bethesda MD, US
Jeffrey Strovel - Laurel MD, US
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
A gene useful as a prognostic indicator of survival of patients afflicted with cancers such as breast cancer is described. Also disclosed are methods for screening potential therapeutic agents, such as antitumor agents, based on their modulation of the expression of a TRIP13 gene, or splice variants thereof, along with methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the expression, or patterns of expression, of such genes, including changes in copy number. Also disclosed are methods for detecting or determining functionally related genes, where disruption of TRIP13 may affect such related-gene expression, as well as methods for treating cancer based on targeting expression products of such genes and determining genes involved in the cancerous process. Methods for identifying, detecting and following patients and others having high levels of amplification/expression of the gene before treatment where differences after treatment serve as markers for indication of success of treatment or for identifying individuals who would benefit from such treatment using this gene marker as a diagnostic and/or prognostic and/or pharmacodynamic or surrogate marker are described.

Determining Cancer-Linked Genes And Therapeutic Targets Using Molecular Cytogenetic Methods

View page
US Patent:
20070059697, Mar 15, 2007
Filed:
Apr 15, 2004
Appl. No.:
10/553098
Inventors:
Jeffrey Strovel - North Potomac MD, US
Colyn Cain - Bethesda MD, US
Stephen Horrigan - Potomac MD, US
Meena Augustus - Gaithersburg MD, US
Assignee:
AVALON PHARMACEUTICALS, INC - Germantown MD
International Classification:
C12Q 1/68
C12P 19/34
US Classification:
435006000, 435091200
Abstract:
Methods for identifying potential therapeutic agents, such as anti-tumor agents, based on their modulation of the expression of specified genes, especially genes mapping to specific chromosomal regions, are disclosed. Also described are methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the expression, or patterns of expression, of such genes, including detecting changes in levels of gene copy number and/or level of amplification of the said gene, or sets of genes, to detect and/or diagnose the cancer. Methods for detecting or determining functionally related genes, as well as methods for treating cancer based on targeting expression products of such genes, determining genes involved in the cancerous process and the success and/or response rates and survival statistics for cancer patients on treatment are encompassed by the invention. Also encompassed are methods involving determining the modulated expression of the genes in these regions of interest (ROIs) as pharmacodynamic/pharmacogenetic /surrogate markers and/or for patient profiling prior to accrual for clinical trials/treatments based on the identification of these genes as validated gene/drug targets in various cancer tissue types.

Cancer-Linked Genes As Targets For Chemotherapy

View page
US Patent:
20080025981, Jan 31, 2008
Filed:
Nov 15, 2006
Appl. No.:
11/599845
Inventors:
Paul Young - Sudbury MA, US
Reinhard Ebner - Gaithersburg MD, US
Zoe Weaver - Ijamsville MD, US
Jeffrey Strovel - Laurel MD, US
Stephen Horrigan - Poolesville MD, US
Martin Shea - Gaithersburg MD, US
Bernd Weigle - Hanau, DE
Michael Rieger - Dresden, DE
Jennifer Rick - Germantown MD, US
Colyn Cain - Bethesda MD, US
International Classification:
A61K 39/395
A61P 35/00
C07K 16/30
C12Q 1/68
US Classification:
424138100, 435006000, 514789000, 530387900
Abstract:
Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with methods for assaying for potential antitumor agents based on their modulation of the expression of these cancer-related genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions, such as using the antibody to target cancerous cells in vivo for purposes of delivering therapeutic agents thereto. Also described are methods of diagnosing cancer using the gene sequences as well as the polypeptide sequences.

Determining Cancer-Linked Genes And Therapeutic Targets Using Molecular Cytogenetic Methods

View page
US Patent:
20080305493, Dec 11, 2008
Filed:
Mar 8, 2005
Appl. No.:
10/591049
Inventors:
Jeffrey W. Strovel - Laurel MD, US
Colyn B. Cain - Bethesda MD, US
Stephen K. Horrigan - Poolesville MD, US
Meena Augustus - Gaithersburg MD, US
Assignee:
AVALON PHARMACEUTICALS - Germantown MD
International Classification:
G01N 33/53
C12Q 1/68
C12Q 1/02
C12N 5/06
G01N 33/566
US Classification:
435 71, 435 6, 436501, 435 29, 435375
Abstract:
Methods for identifying antineoplastic agents by using their ability to modify expression of specific genes or the biological activity of polypeptides encoded by such genes, wherein said genes are located in specific chromosomal regions, called amplicons, or regions of interest, and the presence of such amplified regions within a cancerous cell, are disclosed. Also described are methods for diagnosing cancerous, or potentially cancerous, conditions using these methods. Also encompassed are methods involving determining the modulated expression of the genes in these regions of interest (ROIs), or amplicons, as pharmacodynamic/pharmacogenetic/surrogate markers and/or for patient profiling prior to accrual for clinical trials/treatments based on the identification of these genes as validated gene/drug targets in various cancer tissue types.

Methods For The Cytological Analysis Of Cervical Cells

View page
US Patent:
20100209913, Aug 19, 2010
Filed:
Jul 21, 2009
Appl. No.:
12/506985
Inventors:
Gregory Anton Endress - Belchertown MA, US
Madhvi Upender - Potomac MD, US
Elizabeth Light - Gaithersburg MD, US
Colyn Cain - Bethesda MD, US
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3 q and/or 5p.

Method And System For Automated Image Analysis In Cancer Cells

View page
US Patent:
20110082049, Apr 7, 2011
Filed:
Jul 21, 2010
Appl. No.:
12/840927
Inventors:
Gregory Anton Endress - Belchertown MA, US
Madhvi Upender - Potomac MD, US
Elizabeth Light - Gaithersburg MD, US
Colyn Cain - Bethesda MD, US
Assignee:
NEODIAGNOSTIX, INC. - Rockville MD
International Classification:
C12Q 1/68
C40B 30/04
C12M 1/34
US Classification:
506 9, 435 6, 4352872
Abstract:
A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.

Diagnostic Methods For Oral Cancer

View page
US Patent:
20110086773, Apr 14, 2011
Filed:
Oct 8, 2010
Appl. No.:
12/900996
Inventors:
GREGORY ANTON ENDRESS - BELCHERTOWN MA, US
MADHVI UPENDER - POTOMAC MD, US
ELIZABETH LIGHT - GAITHERSBURG MD, US
COLYN CARGILE CAIN - BETHESDA MD, US
Assignee:
NEODIAGNOSTIX, INC. - ROCKVILLE MD
International Classification:
C40B 30/04
C12Q 1/68
US Classification:
506 9, 435 6
Abstract:
The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose oral cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3, chromosome 5 and chromosome 6 using FISH analysis of probes targeted to 3q and/or 5p and/or 11q.

Method And System For Automated Image Analysis In Cancer Cells

View page
US Patent:
20220177951, Jun 9, 2022
Filed:
Nov 18, 2021
Appl. No.:
17/529405
Inventors:
- Gaithersburg MD, US
Madhvi Upender - Potomac MD, US
Elizabeth Light - Gaithersburg MD, US
Colyn Cargile Cain - Bethesda MD, US
Assignee:
NeoDiagnostix, Inc. - Gaithersburg MD
International Classification:
C12Q 1/6827
C12Q 1/6841
G06T 7/00
G06V 20/69
C12Q 1/6816
Abstract:
A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis: wherein the steps are carried out without intervention by a human.
Control profile
Colyn C Cain from Bethesda, MD, age ~57 Get Report